Oncology/Hematology
News, opinions and meeting coverage in oncology/hematology.
— Phase III trial shows 86% reduction in treated bleeds in hemophilia A and B with inhibitors
Latest in Oncology/Hematology
PPV increased to as much as 44.6% with combined-biomarker screening of high-risk patients
Mezigdomide led to 41% response rate in heavily pretreated patients
Health news and commentary from around the Web gathered by MedPage Today staff
Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top option
Health news and commentary from around the Web gathered by MedPage Today staff
Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top option
Oncology/Hematology Case Studies
Man with a first-degree relative with CRC initially only agreed to stool-based testing
The cause lies in a lengthy history of cancer treatment, confirmed by histopathology analysis
Consistently low PSA levels failed to signal metastasis
More in Oncology/Hematology
A year of DOAC therapy did not result in significantly more bleeds in ONCO DVT trial
Treatments for heart failure, Crohn's disease, and diabetes make the list
Meta-analysis turns up similar findings, though increased ADR overall
A series of articles look at whether the benefits for the few warrant the harms for the many
Researchers flag concerning trends in Vaccines for Children program
News, features, and commentary about cancer-related issues
Time between symptom onset and diagnosis was 21% longer, study shows
Disease progression slowed and need for brain radiation delayed in most patients
Studies show their potential, but reveal clear issues with treatment information reliability
Retrospective data suggest superior survival in pathologically confirmed node-negative disease
More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib
Crystal Denlinger, MD, succeeds Robert Carlson, MD, as CEO of the NCCN
Also in TTHealthWatch: alcohol consumption after a cancer diagnosis
News, features, and commentary about cancer-related issues
